tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Hemolysis D006461 131 associated lipids
Uremia D014511 33 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Stomach Ulcer D013276 75 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Nocardia Infections D009617 6 associated lipids
Diarrhea D003967 32 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Graft Occlusion, Vascular D006083 11 associated lipids
Hypercalcemia D006934 13 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Gao G et al. Rapamycin inhibits hydrogen peroxide-induced loss of vascular contractility. 2011 Am. J. Physiol. Heart Circ. Physiol. pmid:21357511
Ogino A et al. Amlodipine inhibits granulation tissue cell apoptosis through reducing calcineurin activity to attenuate postinfarction cardiac remodeling. 2007 Am. J. Physiol. Heart Circ. Physiol. pmid:17644576
Hafizi S et al. ANG II activates effectors of mTOR via PI3-K signaling in human coronary smooth muscle cells. 2004 Am. J. Physiol. Heart Circ. Physiol. pmid:15317677
Giordano A et al. Rapamycin antagonizes NF-kappaB nuclear translocation activated by TNF-alpha in primary vascular smooth muscle cells and enhances apoptosis. 2006 Am. J. Physiol. Heart Circ. Physiol. pmid:16428340
Kohno M et al. A new cardioprotective agent, JTV519, improves defective channel gating of ryanodine receptor in heart failure. 2003 Am. J. Physiol. Heart Circ. Physiol. pmid:12433661
Sasamori K et al. Cyclic ADP-ribose, a putative Ca2+-mobilizing second messenger, operates in submucosal gland acinar cells. 2004 Am. J. Physiol. Lung Cell Mol. Physiol. pmid:14990397
Lum H et al. Protein phosphatase 2B inhibitor potentiates endothelial PKC activity and barrier dysfunction. 2001 Am. J. Physiol. Lung Cell Mol. Physiol. pmid:11504680
Yaghi A and Sims SM Constrictor-induced translocation of NFAT3 in human and rat pulmonary artery smooth muscle. 2005 Am. J. Physiol. Lung Cell Mol. Physiol. pmid:16055480
Bouvier N et al. Cyclosporine triggers endoplasmic reticulum stress in endothelial cells: a role for endothelial phenotypic changes and death. 2009 Am. J. Physiol. Renal Physiol. pmid:18987109
Ren H et al. Phosphatase inhibition increases AQP2 accumulation in the rat IMCD apical plasma membrane. 2016 Am. J. Physiol. Renal Physiol. pmid:27488997
Thai TL et al. ADP-ribosyl cyclase and ryanodine receptor activity contribute to basal renal vasomotor tone and agonist-induced renal vasoconstriction in vivo. 2007 Am. J. Physiol. Renal Physiol. pmid:17652368
Peherstorfer E et al. Effects of microinjection of synthetic Bcl-2 domain peptides on apoptosis of renal tubular epithelial cells. 2002 Am. J. Physiol. Renal Physiol. pmid:12060601
Axelsson J et al. Scavengers of reactive oxygen species, paracalcitol, RhoA, and Rac-1 inhibitors and tacrolimus inhibit angiotensin II-induced actions on glomerular permeability. 2013 Am. J. Physiol. Renal Physiol. pmid:23657856
Mohebbi N et al. The calcineurin inhibitor FK506 (tacrolimus) is associated with transient metabolic acidosis and altered expression of renal acid-base transport proteins. 2009 Am. J. Physiol. Renal Physiol. pmid:19439519
Cho SG et al. Drp1 dephosphorylation in ATP depletion-induced mitochondrial injury and tubular cell apoptosis. 2010 Am. J. Physiol. Renal Physiol. pmid:20410216
De Miguel C et al. Infiltrating T lymphocytes in the kidney increase oxidative stress and participate in the development of hypertension and renal disease. 2011 Am. J. Physiol. Renal Physiol. pmid:21159736
Rojas-Vega L et al. Increased phosphorylation of the renal Na+-Cl- cotransporter in male kidney transplant recipient patients with hypertension: a prospective cohort. 2015 Am. J. Physiol. Renal Physiol. pmid:26336164
Edinger RS et al. Effect of immunosuppressive agents on glucocorticoid receptor function in A6 cells. 2002 Am. J. Physiol. Renal Physiol. pmid:12110508
Ilori TO et al. Acute calcineurin inhibition with tacrolimus increases phosphorylated UT-A1. 2012 Am. J. Physiol. Renal Physiol. pmid:22205230
Amberg GC et al. Regulation of A-type potassium channels in murine colonic myocytes by phosphatase activity. 2001 Am. J. Physiol., Cell Physiol. pmid:11698261
Ahn HS et al. Calcineurin-independent inhibition of KV1.3 by FK-506 (tacrolimus): a novel pharmacological property. 2007 Am. J. Physiol., Cell Physiol. pmid:17166943
Wang YX et al. FKBP12.6 and cADPR regulation of Ca2+ release in smooth muscle cells. 2004 Am. J. Physiol., Cell Physiol. pmid:14592808
Sans MD and Williams JA Calcineurin is required for translational control of protein synthesis in rat pancreatic acini. 2004 Am. J. Physiol., Cell Physiol. pmid:15044154
Bayguinov O et al. Muscarinic stimulation increases basal Ca(2+) and inhibits spontaneous Ca(2+) transients in murine colonic myocytes. 2001 Am. J. Physiol., Cell Physiol. pmid:11171588
Angus LM et al. Calcineurin-NFAT signaling, together with GABP and peroxisome PGC-1{alpha}, drives utrophin gene expression at the neuromuscular junction. 2005 Am. J. Physiol., Cell Physiol. pmid:15930144
Zhang Y et al. K restriction inhibits protein phosphatase 2B (PP2B) and suppression of PP2B decreases ROMK channel activity in the CCD. 2008 Am. J. Physiol., Cell Physiol. pmid:18184875
Yue G et al. The effect of rapamycin on single ENaC channel activity and phosphorylation in A6 cells. 2000 Am. J. Physiol., Cell Physiol. pmid:10898719
Nam JH et al. Expression of TASK-2 and its upregulation by B cell receptor stimulation in WEHI-231 mouse immature B cells. 2011 Am. J. Physiol., Cell Physiol. pmid:21307343
Nakagawa K et al. Immunosuppression with tacrolimus improved reproductive outcome of women with repeated implantation failure and elevated peripheral blood TH1/TH2 cell ratios. 2015 Am. J. Reprod. Immunol. pmid:25394810
Nakagawa K et al. Immunosuppressive treatment using tacrolimus promotes pregnancy outcome in infertile women with repeated implantation failures. 2017 Am. J. Reprod. Immunol. pmid:28466977
Saito S et al. Role of Paternal Antigen-Specific Treg Cells in Successful Implantation. 2016 Am. J. Reprod. Immunol. pmid:26706630
Kofod L et al. Endometrial immune markers are potential predictors of normal fertility and pregnancy after in vitro fertilization. 2017 Am. J. Reprod. Immunol. pmid:28440588
Tabata C et al. Calcineurin/NFAT pathway: a novel regulator of parturition. 2009 Am. J. Reprod. Immunol. pmid:19527231
Goldthorpe H et al. Occlusive lung arterial lesions in endothelial-targeted, fas-induced apoptosis transgenic mice. 2015 Am. J. Respir. Cell Mol. Biol. pmid:25879383
Fujiki M et al. Role of T cells in bronchoalveolar space in the development of interstitial pneumonia induced by superantigen in autoimmune-prone mice. 1999 Am. J. Respir. Cell Mol. Biol. pmid:10572064
Deuse T et al. Mechanisms behind local immunosuppression using inhaled tacrolimus in preclinical models of lung transplantation. 2010 Am. J. Respir. Cell Mol. Biol. pmid:19880819
Rolfe FG et al. Cyclosporin A and FK506 reduce interleukin-5 mRNA abundance by inhibiting gene transcription. 1997 Am. J. Respir. Cell Mol. Biol. pmid:9271313
Yerkovich ST et al. Survival after bronchiolitis obliterans syndrome. 2011 Am. J. Respir. Crit. Care Med. pmid:21325085
Bhorade S et al. Comparison of sirolimus with azathioprine in a tacrolimus-based immunosuppressive regimen in lung transplantation. 2011 Am. J. Respir. Crit. Care Med. pmid:20833822
Koshika T et al. Pretreatment with FK506 improves survival rate and gas exchange in canine model of acute lung injury. 2001 Am. J. Respir. Crit. Care Med. pmid:11208629
Saeki K et al. Endobronchial Lesions of Mycobacterium abscessus Infection in an Immunocompromised Patient. 2017 Am. J. Respir. Crit. Care Med. pmid:28199133
Joshi MS et al. Calcineurin regulates myocardial function during acute endotoxemia. 2006 Am. J. Respir. Crit. Care Med. pmid:16424445
Fauvel H et al. Protective effects of cyclosporin A from endotoxin-induced myocardial dysfunction and apoptosis in rats. 2002 Am. J. Respir. Crit. Care Med. pmid:11850335
Spiekerkoetter E et al. Low-Dose FK506 (Tacrolimus) in End-Stage Pulmonary Arterial Hypertension. 2015 Am. J. Respir. Crit. Care Med. pmid:26177174
Raofi V et al. A prospective randomized trial comparing the efficacy of tacrolimus versus cyclosporine in black recipients of primary cadaveric renal transplants. 1999 Am. J. Surg. pmid:10326847
Tanaka K et al. Living related liver transplantation in children. 1994 Am. J. Surg. pmid:7517649
Li X et al. Increased iNOS-expressing macrophage in long-term surviving rat small-bowel grafts. 2007 Am. J. Surg. pmid:17618815
Rabkin JM et al. Immunosuppression impact on long-term cardiovascular complications after liver transplantation. 2002 Am. J. Surg. pmid:12034401
Jurim O et al. Living-donor liver transplantation at UCLA. 1995 Am. J. Surg. pmid:7538267
Lee KK et al. Successful treatment of ongoing intestinal allograft rejection permits recovery of graft structure and function. 1993 Am. J. Surg. pmid:7678188
Finn L et al. Epstein-Barr virus infections in children after transplantation of the small intestine. 1998 Am. J. Surg. Pathol. pmid:9500771
Randhawa PS et al. The histopathological changes associated with allograft rejection and drug toxicity in renal transplant recipients maintained on FK506. Clinical significance and comparison with cyclosporine. 1993 Am. J. Surg. Pathol. pmid:7680544
Minervini MI et al. Acute renal allograft rejection with severe tubulitis (Banff 1997 grade IB). 2000 Am. J. Surg. Pathol. pmid:10757402
Randhawa PS et al. Microvascular changes in renal allografts associated with FK506 (Tacrolimus) therapy. 1996 Am. J. Surg. Pathol. pmid:8772784
Reyes J et al. Intestinal transplantation under tacrolimus monotherapy after perioperative lymphoid depletion with rabbit anti-thymocyte globulin (thymoglobulin). 2005 Am. J. Transplant. pmid:15888051
Knoop C et al. Tacrolimus pharmacokinetics and dose monitoring after lung transplantation for cystic fibrosis and other conditions. 2005 Am. J. Transplant. pmid:15888057
Kandaswamy R et al. A prospective randomized trial of steroid-free maintenance regimens in kidney transplant recipients--an interim analysis. 2005 Am. J. Transplant. pmid:15888064
Cavadas PC et al. Bilateral trans-humeral arm transplantation: result at 2 years. 2011 Am. J. Transplant. pmid:21521475
Qazi Y et al. Efficacy and Safety of Everolimus Plus Low-Dose Tacrolimus Versus Mycophenolate Mofetil Plus Standard-Dose Tacrolimus in De Novo Renal Transplant Recipients: 12-Month Data. 2017 Am. J. Transplant. pmid:27775865
Egli A et al. Renal failure five years after lung transplantation due to polyomavirus BK-associated nephropathy. 2010 Am. J. Transplant. pmid:20840474
Zafrani L et al. Incidence, risk factors and clinical consequences of neutropenia following kidney transplantation: a retrospective study. 2009 Am. J. Transplant. pmid:19538494
Touzot M et al. Renal transplantation in HIV-infected patients: the Paris experience. 2010 Am. J. Transplant. pmid:20840478
Krämer BK et al. Tacrolimus once daily (ADVAGRAF) versus twice daily (PROGRAF) in de novo renal transplantation: a randomized phase III study. 2010 Am. J. Transplant. pmid:20840480
Trunečka P et al. Once-daily prolonged-release tacrolimus (ADVAGRAF) versus twice-daily tacrolimus (PROGRAF) in liver transplantation. 2010 Am. J. Transplant. pmid:20840481
Wang Q et al. Biodegradable microsphere-loaded tacrolimus enhanced the effect on mice islet allograft and reduced the adverse effect on insulin secretion. 2004 Am. J. Transplant. pmid:15084166
Schubert M et al. Pharmacokinetics of sirolimus and tacrolimus in pediatric transplant patients. 2004 Am. J. Transplant. pmid:15084173
ter Meulen CG et al. Steroid-withdrawal at 3 days after renal transplantation with anti-IL-2 receptor alpha therapy: a prospective, randomized, multicenter study. 2004 Am. J. Transplant. pmid:15084178
Budde K et al. Novel once-daily extended-release tacrolimus (LCPT) versus twice-daily tacrolimus in de novo kidney transplants: one-year results of Phase III, double-blind, randomized trial. 2014 Am. J. Transplant. pmid:25278376
O'Grady JG et al. Randomized controlled trial of tacrolimus versus microemulsified cyclosporin (TMC) in liver transplantation: poststudy surveillance to 3 years. 2007 Am. J. Transplant. pmid:17109723
Böhmig GA et al. Immunoadsorption in severe C4d-positive acute kidney allograft rejection: a randomized controlled trial. 2007 Am. J. Transplant. pmid:17109725
Budde K et al. Sotrastaurin, a novel small molecule inhibiting protein kinase C: first clinical results in renal-transplant recipients. 2010 Am. J. Transplant. pmid:20121745
Hanto DW et al. Intraoperative administration of inhaled carbon monoxide reduces delayed graft function in kidney allografts in Swine. 2010 Am. J. Transplant. pmid:20977633
Al-Massarani G et al. Impact of immunosuppressive treatment on endothelial biomarkers after kidney transplantation. 2008 Am. J. Transplant. pmid:18925903
Frassetto LA and Benet LZ Pharmacogenomics and transplantation: where are we? 2004 Am. J. Transplant. pmid:15147415
MacPhee IA et al. The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation. 2004 Am. J. Transplant. pmid:15147425
Artz MA et al. Conversion from cyclosporine to tacrolimus improves quality-of-life indices, renal graft function and cardiovascular risk profile. 2004 Am. J. Transplant. pmid:15147428
Hamdy AF et al. Comparison of sirolimus with low-dose tacrolimus versus sirolimus-based calcineurin inhibitor-free regimen in live donor renal transplantation. 2005 Am. J. Transplant. pmid:16162204
Kaufman DB et al. Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: comparison with basiliximab induction--long-term results. 2005 Am. J. Transplant. pmid:16162205
Chisholm-Burns MA et al. Improving outcomes of renal transplant recipients with behavioral adherence contracts: a randomized controlled trial. 2013 Am. J. Transplant. pmid:23819827
Troppmann C et al. Impact of portal venous pancreas graft drainage on kidney graft outcome in simultaneous pancreas-kidney recipients reported to UNOS. 2004 Am. J. Transplant. pmid:15023146
Muthusamy AS et al. Alemtuzumab induction and steroid-free maintenance immunosuppression in pancreas transplantation. 2008 Am. J. Transplant. pmid:18828772
Van Laecke S et al. Posttransplantation hypomagnesemia and its relation with immunosuppression as predictors of new-onset diabetes after transplantation. 2009 Am. J. Transplant. pmid:19624560
Pirenne J et al. Tolerance of liver transplant patients to strenuous physical activity in high-altitude. 2004 Am. J. Transplant. pmid:15023147
Heisel O et al. New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. 2004 Am. J. Transplant. pmid:15023151
Hardinger KL et al. Pharmacokinetics of tacrolimus in kidney transplant recipients: twice daily versus once daily dosing. 2004 Am. J. Transplant. pmid:15023155
Srinivas TR et al. The noninferiority trial: don't don't do it. 2010 Am. J. Transplant. pmid:21087412
Kohnle M et al. Ezetimibe for the treatment of uncontrolled hypercholesterolemia in patients with high-dose statin therapy after renal transplantation. 2006 Am. J. Transplant. pmid:16433776
Larson TS et al. Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. 2006 Am. J. Transplant. pmid:16468960
Luan FL et al. Comparative risk of impaired glucose metabolism associated with cyclosporine versus tacrolimus in the late posttransplant period. 2008 Am. J. Transplant. pmid:18786231
Woywodt A et al. Different preparations of tacrolimus and medication errors. 2008 Am. J. Transplant. pmid:18786238
Servais A et al. Interstitial fibrosis evolution on early sequential screening renal allograft biopsies using quantitative image analysis. 2011 Am. J. Transplant. pmid:21672152
Levi Z et al. Switching from tacrolimus to sirolimus halts the appearance of new sebaceous neoplasms in Muir-Torre syndrome. 2007 Am. J. Transplant. pmid:17229076
Ogawa T et al. Rho-associated kinase inhibitor reduces tumor recurrence after liver transplantation in a rat hepatoma model. 2007 Am. J. Transplant. pmid:17229077
Miriuka SG et al. mTOR inhibition induces endothelial progenitor cell death. 2006 Am. J. Transplant. pmid:16796720
Ryan CM and Swanson DP clinical research, innovative practice and IRB review: identifying and respecting boundaries. 2007 Am. J. Transplant. pmid:17331113
Rostaing L et al. Alefacept combined with tacrolimus, mycophenolate mofetil and steroids in de novo kidney transplantation: a randomized controlled trial. 2013 Am. J. Transplant. pmid:23730730
Levy G et al. REFINE: a randomized trial comparing cyclosporine A and tacrolimus on fibrosis after liver transplantation for hepatitis C. 2014 Am. J. Transplant. pmid:24456049
Ciancio G et al. Advantage of rapamycin over mycophenolate mofetil when used with tacrolimus for simultaneous pancreas kidney transplants: randomized, single-center trial at 10 years. 2012 Am. J. Transplant. pmid:22946986
Jacobson PA et al. Lower calcineurin inhibitor doses in older compared to younger kidney transplant recipients yield similar troughs. 2012 Am. J. Transplant. pmid:22947444
Miller LW Cardiovascular toxicities of immunosuppressive agents. 2002 Am. J. Transplant. pmid:12392286